Phase 2 Ovarian Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with returning ovarian cancer, fallopian tube cancer, or primary peritoneal cancer of a specific type, confirmed through laboratory testing of tissue or cell samples (specific cancer types include high-grade serous carcinoma or grade 2/3 endometrioid carcinoma).
- People whose BRCA 1/2 gene mutation status and/or a genetic marker called Homologous Recombination Deficiency (HRD) status has been tested and confirmed (confirm with trial site for specific requirements).
- People who have previously received platinum-based chemotherapy followed by a type of maintenance therapy called a PARP inhibitor.
- People who received chemotherapy before joining the trial and whose cancer responded to platinum-based chemotherapy.
- People with a general health and activity level rated as 0 or 1 on a standard medical scale, meaning they are fully active or have only minor limitations in physically demanding activities.
- People with confirmed adequate blood, kidney, and liver function, as measured by laboratory tests during the screening process.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with a history of severe allergic or hypersensitivity reactions to the study drug, its ingredients, or similar types of drugs.
- People who have difficulty swallowing.
- People with a confirmed specific medical history or past surgical history (confirm with trial site for details).
- People with certain other health conditions or medical abnormalities (confirm with trial site for details).
- People who are pregnant, breastfeeding, or able to become pregnant and do not agree to use appropriate contraception throughout the trial and for 24 weeks after the last dose of the study drug.
- People who have taken part in another clinical trial or received an investigational medical device procedure within 4 weeks before the start of the trial.
- People considered by the treating doctor to be otherwise unsuitable or unable to take part in this study for any reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: + 82-2-3454-0780
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part A: Maximum tolerated dose (MTD) and recommended dose (RD)(RP2D); Part B: Progression free survival(PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.